期刊
CLEVELAND CLINIC JOURNAL OF MEDICINE
卷 70, 期 7, 页码 585-+出版社
CLEVELAND CLINIC
DOI: 10.3949/ccjm.70.7.585
关键词
-
Forteo (teriparaticle of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据